Fig. 4From: Relugolix for oral treatment of uterine leiomyomas: a dose-finding, randomized, controlled trialSecondary efficacy endpoints: proportion of patients with a total pictorial blood loss assessment chart (PBAC) score of 0 for weeks 6−12Back to article page